Docetaxel–Cyclophosphamide Chemotherapy Protocol for Breast Cancer

The docetaxel–cyclophosphamide (TC) chemotherapy protocol is an effective, relatively well-tolerated regimen commonly used to treat early-stage breast cancer. It is particularly preferred for patients with HER2-negative, node-negative disease.

T – Taxotere (Docetaxel): Docetaxel

C – Cyclophosphamide (Endoksan): Cyclophosphamide

Docetaxel

• Docetaxel is a semisynthetic chemotherapy drug derived from the needles of the yew tree.
• It binds strongly to microtubules, an important component of the cell's cytoskeleton, and stabilizes them. This binding prevents microtubules from moving flexibly as they normally should, stopping cell division.
• Docetaxel acts during mitosis, the division phase of the cell cycle. By stopping cells from dividing and multiplying, it inhibits the growth of cancer cells.

Cyclophosphamide

• Cyclophosphamide is an alkylating chemotherapy agent that damages DNA and causes cancer-cell death. It is widely used for both solid tumors, such as breast cancer, and hematological cancers, including leukemia and lymphoma.
• After conversion to its active form in the body, it attaches alkyl groups to DNA strands. This prevents DNA from being copied correctly and inhibits cell division, resulting in apoptosis, or programmed cell death, particularly in rapidly dividing cancer cells.

Treatment Goals

Adjuvant Treatment (After Surgery):

• Eliminate microscopic cancer cells that may remain in the body after surgery.
• Reduce the risk of recurrence.
• Improve long-term disease-free survival.

Neoadjuvant Treatment (Before Surgery):

• Shrink the tumor to facilitate surgery and make breast-conserving surgery possible.
• Assess the response to treatment.

Curative Intent:

• Aim for complete recovery in early-stage disease, particularly in patients with node-negative, HER2-negative cancer.

Treatment Indications

Early-Stage Breast Cancer (As Adjuvant Treatment):

Used after surgical removal of the tumor to eliminate microscopic cancer cells that may remain in the body.

Particularly recommended for the following groups:

• Patients with node-negative (N0) disease
• HER2-negative tumors
• Hormone receptor (ER/PR)-positive or triple-negative tumors
• Tumor size ≥1 cm, high grade, high Ki-67, or other adverse prognostic features

Neoadjuvant Treatment (Before Surgery):

• To shrink the tumor and facilitate surgery, particularly breast-conserving surgery
• In patients with clinically positive lymph nodes but uncertainty about surgical margins

Patients Not Suitable for Hormonal Therapy:

Chemotherapy is indicated in patients with early-stage hormone receptor-negative (ER-, PR-) disease; TC may be preferred in this setting.

Patients Not Suitable for Alternative Regimens:

In patients unsuitable for anthracycline-containing regimens, such as AC → T, because of cardiotoxicity, the anthracycline-free TC regimen is a safe alternative.

Situations in Which Treatment Is Unsuitable

• Severe Cardiovascular Disease: Heart failure, uncontrolled hypertension, or cardiomyopathy after previous anthracycline use. Caution is particularly important because docetaxel can cause fluid retention.
• Bone Marrow Failure / Severe Myelosuppression: If severe anemia, leukopenia, or thrombocytopenia is already present and blood counts are inadequate, the dose should be delayed or the protocol changed
• History of Severe Allergic Reactions: Patients with a history of severe allergy to docetaxel or its polysorbate 80 vehicle. Patients with hypersensitivity to cyclophosphamide.
• Low-Risk Early-Stage Breast Cancer: In postmenopausal patients with a tumor ≤0.5 cm, negative lymph nodes, low grade, low Ki-67, and hormone receptor positivity, hormonal therapy alone may be sufficient instead of chemotherapy. TC may constitute overtreatment in these patients.
• Poor Performance Status / Older Patients: Older patients with comorbidities and an ECOG performance score ≥2 are at high risk of toxicity. Alternative regimens with lower toxicity may be preferred.
• Liver or Kidney Impairment: Caution is needed, particularly because docetaxel is metabolized in the liver and cyclophosphamide is eliminated through the kidneys. Elevated liver enzymes (AST/ALT) or bilirubin require attention. Dose reduction or an alternative may be needed in patients with creatinine clearance <30 ml/min.
• Pregnancy and Breastfeeding: Cyclophosphamide and docetaxel are both fetotoxic and teratogenic. They are strictly contraindicated during pregnancy.

SGK Reimbursement Status

In Turkey, combination treatment with docetaxel and cyclophosphamide is routinely reimbursed by the Social Security Institution (SGK).

Dosage and Administration

Cyclophosphamide: 600 mg/m², day 1

Docetaxel: 75 mg/m², day 1

Frequency: Every 21 days

Total Number of Cycles: Usually 4 cycles

Route: Intravenous (IV) infusion

Premedication:

• Dexamethasone 8 mg orally (PO) twice daily for 3 days, starting one day before docetaxel administration.
• 5-HT3 antagonists, such as ondansetron or granisetron, and dexamethasone also provide antiemetic effects. Because this regimen is moderately emetogenic, this combination is generally sufficient.
• If needed, antihistamines for patients at high risk of allergy or a proton pump inhibitor for gastric protection are added to premedication.

Situations Requiring Attention

• Blood Counts (Hematological Monitoring): A complete blood count must be performed before and between treatments. Leukopenia/neutropenia and infection risks are high. G-CSF (filgrastim) support is given if needed.
• Risk of Allergic Reactions: Docetaxel in particular can cause severe allergic reactions, so dexamethasone premedication is essential. Caution is required in patients with an allergy history.
• Risk of Infection: Immunity may be suppressed. Patients should contact their physician immediately for fever, chills, sore throat, or urinary symptoms. Febrile neutropenia requires emergency intervention.
• Drug Interactions: Caution is needed with drugs metabolized by the liver, such as anticoagulants or antiepileptics. All medications should be reviewed by an oncology pharmacist.
• Skin and Nail Toxicity: Docetaxel may cause onycholysis, or nail separation, and skin rash. Cold gloves may reduce these effects (15 minutes before–15 minutes after).
• Fluid Retention / Edema: This is one of docetaxel's most common adverse effects. Monitor leg swelling and weight gain. Dexamethasone helps reduce it.
• Pregnancy and Fertility: Cyclophosphamide and docetaxel are teratogenic, and pregnancy is strictly contraindicated. Fertility counseling should be provided before treatment.
• Older Patients or Those With Comorbidities: Older patients and those with poor performance status may require dose reduction or a different regimen.
• Liver and Kidney Function: Cyclophosphamide is eliminated through the kidneys and docetaxel through the liver. Dose adjustment is needed if AST/ALT or creatinine is elevated.
• Adherence and Follow-Up: Regular follow-up every 3 weeks is important. Report all adverse effects to the physician, including nausea, fatigue, fever, diarrhea, constipation, or mouth sores.